StockNews.com upgraded shares of Encompass Health (NYSE:EHC – Free Report) from a hold rating to a buy rating in a report issued on Saturday morning.
A number of other equities analysts have also commented on the stock. Truist Financial reaffirmed a “buy” rating and set a $116.00 price target (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Barclays raised their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $110.00 price target on shares of Encompass Health in a research report on Tuesday, February 11th. Finally, KeyCorp raised their target price on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Encompass Health presently has a consensus rating of “Buy” and an average target price of $107.67.
Check Out Our Latest Stock Analysis on Encompass Health
Encompass Health Price Performance
Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 18.06%. Equities analysts forecast that Encompass Health will post 4.76 EPS for the current year.
Insider Activity
In other news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Encompass Health
A number of hedge funds have recently made changes to their positions in EHC. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Encompass Health in the 3rd quarter valued at approximately $40,000. Transce3nd LLC acquired a new stake in shares of Encompass Health in the 4th quarter valued at approximately $40,000. Finally, CBIZ Investment Advisory Services LLC boosted its stake in shares of Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock valued at $42,000 after purchasing an additional 127 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Further Reading
- Five stocks we like better than Encompass Health
- About the Markup Calculator
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- How to Calculate Options Profits
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Are Penny Stocks a Good Fit for Your Portfolio?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.